Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Review, H2 2016', provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted pipeline therapeutics. 

The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) 
- The report reviews Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) Overview 6
Therapeutics Development 7
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Stage of Development 7
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Therapy Area 8
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Indication 9
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Pipeline Products Glance 10
Early Stage Products 10
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Products under Development by Companies 11
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Therapeutics Assessment 13
Assessment by Monotherapy/Combination Products 13
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Companies Involved in Therapeutics Development 18
ContraVir Pharmaceuticals Inc 18
Cypralis Ltd 19
Debiopharm International SA 20
Enanta Pharmaceuticals Inc 21
Ensemble Therapeutics Corp 22
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Drug Profiles 23
alisporivir - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
alisporivir + EDP-239 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
CRV-431 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecules to Inhibit Cyclophilin A for Hepatitis B - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecules to Inhibit Cyclophilin A for Inflammation - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Dormant Projects 32
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Discontinued Products 33
Peptidyl Prolyl Cis Trans Isomerase A (Cyclophilin A or Cyclosporin A Binding Protein or Rotamase A or PPIA or EC 5.2.1.8) - Featured News & Press Releases 34
Dec 08, 2016: ContraVirs Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B 34
Sep 12, 2016: ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B 34
Aug 22, 2016: ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B 35
Apr 19, 2016: Ciclofilin Pharmaceuticals Invited to Present Hepatitis B Drug Data at Cambridge Healthtech Institute's Eleventh Annual Drug Discovery Chemistry Conference 36
Feb 04, 2016: Ciclofilin Pharmaceuticals Welcomes Dr. Nikolai Naoumov to Its Scientific Advisory Board 36
Dec 02, 2015: Ciclofilin Pharmaceuticals Announces Formation of World-Class HBV and Liver Disease Scientific Advisory Board 37
Nov 30, 2015: Ciclofilin Pharmaceuticals to Present at HEP DART 2015 39
Sep 08, 2015: Debiopharm International and Solid Biosciences Announce a Collaboration to Explore the Use of Alisporivir in Muscular Dystrophy 40
Aug 04, 2015: Ciclofilin Pharmaceuticals Receives Notice of Patent Allowance for Novel Cyclophilin Inhibitor 40
Jul 28, 2015: Ciclofilin Pharmaceuticals' Lead Antiviral Drug Reduces Liver HBV DNA 41
Jun 24, 2015: Ciclofilin Pharmaceuticals' HBV Drug Demonstrates Anti-Fibrotic Activity 41
Feb 24, 2015: Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs 42
Feb 17, 2015: Ciclofilin Pharmaceuticals to Present HBV/HIV/HCV Co-Infection Results at EASL 2015 42
Nov 13, 2014: The Government of Canada Provides Support to Ciclofilin Pharmaceuticals for the Pre-Clinical Development of Its Lead Drug 43
Nov 04, 2014: Ciclofilin Pharmaceuticals to Present HIV/HCV Co-Infection Results at AASLD in Boston on November 11 43

Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Products under Development by Companies, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 13
Number of Products by Stage and Mechanism of Action, H2 2016 14
Number of Products by Stage and Route of Administration, H2 2016 15
Number of Products by Stage and Molecule Type, H2 2016 17
Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 18
Pipeline by Cypralis Ltd, H2 2016 19
Pipeline by Debiopharm International SA, H2 2016 20
Pipeline by Enanta Pharmaceuticals Inc, H2 2016 21
Pipeline by Ensemble Therapeutics Corp, H2 2016 22
Dormant Projects, H2 2016 32
Discontinued Products, H2 2016 33